FrancophonIA/ELRC3.0 huggingface dataset:
English: A GLP compliant residue depletion study was provided by one of the marketing authorisation holders involved in the procedure, and while a number of shortcoming on the study design were identified, the data allowed the recommendation to have a 42 day withdrawal period for meat and offal for 49 out of the 50 concerned products, i.e., for products containing 50 mg/ml and 200 mg/ml tylosin as a solution for injection for intramuscular use in sheep, containing benzyl alcohol and propylene glycol as excipients.
Croatian: Iako je u pogledu izvedbe ispitivanja utvrđen niz nedostataka, ti su podatci omogućili donošenje preporuke da razdoblje karencije za meso i iznutrice za 49 od 50 predmetnih VMP-ova iznosi 42 dana, tj. za VMP-ove koji sadržavaju 50 mg/ml i 200 mg/ml tilozina u obliku otopine za injekciju za intramuskularnu primjenu u ovaca, a kao pomoćne tvari sadržavaju benzilni alkohol i propilen glikol.
English: Cattle, goats, pigs,
Croatian: Goveda, koze, svinje,
English: For sheep over 50 kg of bodyweight, the CVMP recommends that the dose is divided over two injection sites.
Croatian: Za ovce teže od 50 kg tjelesne težine, CVMP preporučuje da se doza podijeli na dva mjesta primjene injekcije.
English: 5 CVMP note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95) - link the influence of increasing the injection volume/site of injection on the absorption rate is difficult to quantify.
Croatian: 5 CVMP note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95) - link
English: Hence, data from this study could not be extrapolated to the only product containing the excipient polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), for the reason mentioned above.
Croatian: Stoga se, zbog prethodno navedenog razloga, podatci iz ovog ispitivanja nisu mogli koristiti za ekstrapolaciju na jedini VMP koji sadržava pomoćnu tvar polietilen glikol 400 (Tilocen, nositelj odobrenja za stavljanje VMP-a u promet: A.
English: No proprietary residue depletion studies in ewes were submitted.
Croatian: Nisu dostavljena vlasnička ispitivanja o izlučivanju rezidua u ovaca.
English: For one product (Tilocen), the solvent polyethylene glycol 400 was used instead of propylene glycol.
Croatian: U jednom VMP-u (Tilocen) umjesto propilen glikola koristilo se otapalo polietilen glikol 400.
English: The CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1)1 allows extrapolation of the withdrawal period between animal species, but only from a major species to a minor species.
Croatian: U Smjernicama CVMP-a o zahtjevima u pogledu podataka o sigurnosti i reziduama za veterinarskomedicinske proizvode namijenjene manjoj upotrebi ili manje zastupljenim vrstama (MUMS)/ograničenom tržištu (EMA/CVMP/SWP/66781/2005-Rev.1)1 omogućuje se ekstrapolacija razdoblja karencije među životinjskim vrstama, ali samo s više zastupljene životinjske vrste na manje zastupljenu vrstu.
English: There are 50 products within the scope of this referral procedure.
Croatian: Ovim arbitražnim postupkom obuhvaćeno je 50 VMP-ova.
English: While the residue studies mentioned above were made available, milk from sheep is considered a minor food commodity, and withdrawal periods for sheep milk can be extrapolated from those for cows' milk in accordance with the CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1).
Croatian: Iako su prethodno navedena ispitivanja rezidua stavljena na raspolaganje, mlijeko ovaca smatra se manje zastupljenim prehrambenim proizvodom, a razdoblje karencije za mlijeko ovaca može se ekstrapolirati iz razdoblja karencije za kravlje mlijeko u skladu sa Smjernicama CVMP-a o zahtjevima u pogledu podataka o sigurnosti i reziduama za veterinarsko-medicinske proizvode namijenjene manjoj upotrebi ili manje zastupljenim vrstama (MUMS) / ograničenom tržištu (EMA/CVMP/SWP/66781/2005Rev.1).
English: PHARMASIN 200 mg/ml soluzione iniettabile per
Croatian: Pharmasin 200 mg/ml solution for injection for
English: For sheep over 50 kg, the CVMP recommends that the dose is divided over two injection sites.
Croatian: Za ovce teže od 50 kg CVMP preporučuje da se doza podijeli na dva mjesta primjene injekcije.
English: Milk from sheep is, however, considered a minor food commodity, and withdrawal periods for sheep milk can be extrapolated from those for cows' milk, in accordance with the CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1).
Croatian: Međutim, mlijeko ovaca smatra se manje zastupljenim prehrambenim proizvodom, a razdoblje karencije za mlijeko ovaca može se ekstrapolirati iz razdoblja karencije za kravlje mlijeko u skladu sa Smjernicama CVMP-a o zahtjevima u pogledu podataka o sigurnosti i reziduama za veterinarskomedicinske proizvode namijenjene manjoj upotrebi ili manje zastupljenim vrstama (MUMS) / ograničenom tržištu (EMA/CVMP/SWP/66781/2005-Rev.1).
English: Cattle, sheep, pigs, dogs, cats
Croatian: Goveda, ovce, svinje, psi, mačke
English: The other publically available study showed that residues in sheep milk were
Croatian: U drugom javnom dostupnom ispitivanju dokazano je da su koncentracije
English: Solution for
Croatian: Otopina za
English: 4.9 Amounts to be administered and administration route For sheep over 50 kg of bodyweight, the injection should be divided over two injection sites (maximum 2.5 ml injection volume per injection site).
Croatian: Za ovce iznad 50 kg tjelesne težine injekciju treba podijeliti na dva mjesta primjene (najviše 2,5 ml volumena injekcije po mjestu primjene injekcije).
English: Tylosin 200
Croatian: baza tilozina 200
English: Cats, cattle, dogs, goats, pigs, sheep
Croatian: Mačke, goveda, psi, koze, svinje, ovce
English: It is noted that a withdrawal period of 42 days for meat and offal is currently established for several of the products within this referral procedure.
Croatian: Primijećeno je da se za nekoliko VMP-ova obuhvaćenih ovim arbitražnim postupkom trenutačno uspostavlja razdoblje karencije od 42 dana za meso i iznutrice.
English: A GLP-compliant residue study with tylosin solution for injection, conducted in sheep via intramuscular administration was made available to CVMP.
Croatian: CVMP-u je dostavljeno ispitivanje rezidua u skladu s dobrom laboratorijskom praksom s otopinom tilozina za injekciju provedeno na ovcama putem intramuskularne primjene.
English: Cattle, dogs, goats, pigs, sheep
Croatian: Goveda, psi, koze, svinje, ovce
English: Data from this study could not be used as a basis for extrapolating the withdrawal period for the only product containing the excipient polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), as differences between the absorption of residues from the injection site for these two products (i.e., given the differences on viscosities from products with different excipients) cannot be excluded, as mentioned in the section above.
Croatian: Nikolakopoulos S.A), jer se razlike između apsorpcije rezidua s mjesta primjene injekcije za ova dva VMP-a (tj. s obzirom na razlike u viskoznosti VMP-ova s različitim pomoćnim tvarima) ne mogu isključiti, kao što je spomenuto u prethodnom tekstu.
English: For only one concerned product (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), the solvent polyethylene glycol 400 is used instead of propylene glycol.
Croatian: Nikolakopoulos S.A) koristi se otapalo polietilen glikol 400 umjesto propilen glikola.
English: • no suitable residue depletion study was made available the results from which could be extrapolated to the concerned product Tilocen (marketing authorisation holder: A. Nikolakopoulos S.A) containing tylosin presented as solution for injection for use in the target species sheep, and containing polyethylene glycol 400 as excipient.
Croatian: • Nije dostavljeno odgovarajuće ispitivanje o izlučivanju rezidua koje bi se moglo ekstrapolirati na predmetni VMP Tilocen (nositelj odobrenja za stavljanje VMP-a u promet: A.
English: For the product containing the excipient polyethylene glycol 400 (Tilocen, marketing authorisation holder: A. Nikolakopoulos S.A), no suitable residue depletion data are available for establishing a withdrawal period for sheep meat, offal, and milk.
Croatian: Nikolakopoulos S.A) nisu dostupni odgovarajući podatci o izlučivanju rezidua za utvrđivanje razdoblja karencije za meso, iznutrice i mlijeko ovaca.
English: PHARMASIN 200 mg/ml injekcinis tirpalas kiaulėms, galvijams, avims ir ožkoms
Croatian: PHARMASIN 200 mg/ml injekcinis tirpalas kiaulėms, galvijams,
English: Tylosin/Anafasis
Croatian: Tylosin/Anafasis tilozin tartarat 200 mg/ml
English: Milk from sheep is considered a minor food commodity, and in line with the CVMP guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (EMA/CVMP/SWP/66781/2005-Rev.1) extrapolation can be done from cow's milk to sheep milk.
Croatian: Mlijeko ovaca smatra se manje zastupljenim prehrambenim proizvodom te se podatci o kravljem mlijeku mogu ekstrapolirati na mlijeko ovaca u skladu sa Smjernicama CVMP-a o zahtjevima u pogledu podataka o sigurnosti i reziduama za veterinarsko-medicinske proizvode namijenjene manjoj upotrebi ili manje zastupljenim vrstama (MUMS) / ograničenom tržištu (EMA/CVMP/SWP/66781/2005- Rev.1).
English: This medicine is the same as CoAprovel, which is already authorised in the European Union (EU).
Croatian: Ovaj lijek je isti kao i CoAprovel, koji je već odobren u Europskoj uniji (EU).
English: Irbesartan on its own has been approved in the EU since 1997 under the names Karvea and Aprovel.
Croatian: Irbesartan je pojedinačno odobren u EU-u od 1997. pod nazivima Karvea i Aprovel.
English: This summary was last updated in 07-2013.
Croatian: Sažetak je posljednji put dopunjen u srpnju 2013.
English: The full EPAR for Irbesartan Hydrochlorothiazide Zentiva can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za Irbesartan Hydrochlorothiazide Zentiva može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The full list of these medicines is given in the package leaflet.
Croatian: Cijeli popis ovih lijekova navodi se u uputi o lijeku.
English: Doses higher than 300 mg irbesartan and
Croatian: Ne preporučuju se doze veće od 300 mg irbesartana i
English: 25 mg hydrochlorothiazide once a day are not recommended.
Croatian: 25 mg hidroklorotiazida jednom na dan.
English: The name of the medicine was changed to Irbesartan Hydrochlorothiazide Zentiva on 6 February 2012.
Croatian: Naziv lijeka promijenjen je u Irbesartan Hydrochlorothiazide Zentiva 6. veljače 2012.
English: For more information about treatment with Irbesartan Hydrochlorothiazide Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Irbesartan Hydrochlorothiazide Zentiva pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Irbesartan Hydrochlorothiazide Winthrop on 19 January 2007.
Croatian: Europska komisija izdaje odobrenje za stavljanje u promet koje za Irbesartan Hydrochlorothiazide Winthrop vrijedi na prostoru Europske unije od 19. siječnja 2007.
English: The company that makes CoAprovel has agreed that its scientific data can be used for Irbesartan Hydrochlorothiazide Zentiva.
Croatian: Farmaceutska tvrtka koja proizvodi CoAprovel pristala je da se njeni znanstveni podaci koriste za lijek Irbesartan Hydrochlorothiazide Zentiva.
English: Previously known as Irbesartan Hydrochlorothiazide Winthrop.
Croatian: Prethodno poznat kao Irbesartan Hydrochlorothiazide Winthrop.
English: Irbesartan Hydrochlorothiazide Zentiva was more effective than placebo (a dummy treatment) and than hydrochlorothiazide alone in reducing diastolic blood pressure.
Croatian: Lijek Irbesartan Hydrochlorothiazide Zentiva bio je učinkovitiji od placeba (liječenje bez djelatne tvari) i od samog hidroklorotiazida u smanjenju dijastoličkog krvnog tlaka.
English: Irbesartan Hydrochlorothiazide Zentiva may be added to some other treatments for hypertension.
Croatian: Irbesartan Hydrochlorothiazide Zentiva se može dodati nekim drugim načinima liječenja hipertenzije.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Irbesartan Hydrochlorothiazide Zentiva.
Croatian: Objašnjava kako je Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) ocijenilo lijek da bi preporučilo njegovo odobrenje za stavljanje u promet te uključuje preporuke Povjerenstva o uvjetima za primjenu lijeka Irbesartan Hydrochlorothiazide Zentiva.
English: The studies of Karvea/Aprovel used with hydrochlorothiazide as separate tablets were used to support the use of Irbesartan Hydrochlorothiazide Zentiva.
Croatian: Ispitivanja lijekova Karvea/Aprovel korištenih uz hidroklorotiazid u obliku odvojenih tableta korištena su za podržavanje uporabe lijeka Irbesartan Hydrochlorothiazide Zentiva.
English: This is a summary of the European public assessment report (EPAR) for Irbesartan Hydrochlorothiazide Zentiva.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za Irbesartan Hydrochlorothiazide Zentiva.
English: Irbesartan Hydrochlorothiazide Zentiva must not be used in people who are hypersensitive (allergic) to irbesartan, hydrochlorothiazide, sulfonamides, or any of the other ingredients.
Croatian: Irbesartan Hydrochlorothiazide Zentiva se ne smije upotrebljavati kod osoba koje su preosjetljive (alergične) na irbesartan, hidroklorotiazid, sulfonamide ili neku od drugih sastavnica.
English: Irbesartan Hydrochlorothiazide Zentiva in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Croatian: Irbesartan Hydrochlorothiazide Zentiva u kombinaciji s lijekovima koji sadrže aliskiren (koristi se za liječenje esencijalne hipertenzije) ne smije se koristiti kod bolesnika sa šećernom bolešću ili umjerenim ili teškim oštećenjem bubrega.
English: The dose of Irbesartan Hydrochlorothiazide Zentiva to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before.
Croatian: Doza lijeka Irbesartan Hydrochlorothiazide Zentiva koja se koristi ovisi o dozi irbesartana ili hidroklorotiazida koju je bolesnik uzimao prije.
English: The CHMP decided that Irbesartan Hydrochlorothiazide Zentiva's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) odlučilo je da koristi od lijeka Irbesartan Hydrochlorothiazide Zentiva nadmašuju s njim povezane rizike te je preporučilo njegovo odobrenje za stavljanje u promet.
English: The most common side effects with Irbesartan Hydrochlorothiazide Zentiva (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscles).
Croatian: Najčešće nuspojave lijeka Irbesartan Hydrochlorothiazide Zentiva (koje se mogu javiti u 1 do 10 na 100 osoba) su vrtoglavica, mučnina (osjećaj slabosti) ili povraćanje, neuobičajeno mokrenje, umor (zamor) i povećanje koncentracije dušika iz ureje u krvi (eng.
English: Other information about Irbesartan Hydrochlorothiazide Zentiva
Croatian: Druge informacije o lijeku Irbesartan Hydrochlorothiazide Zentiva
English: Irbesartan Hydrochlorothiazide Zentiva is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.
Croatian: Irbesartan Hydrochlorothiazide Zentiva je lijek koji sadrži dvije djelatne tvari, irbesartan i hidroklorotiazid.
English: EPAR summary for the public irbesartan / hydrochlorothiazide
Croatian: EPAR, sažetak za javnost irbesartan/hidroklorotiazid
English: Irbesartan Hydrochlorothiazide Zentiva must also not be used in patients who have severe liver, kidney or bile problems, blood potassium levels that are too low or blood calcium levels that are too high.
Croatian: Irbesartan Hydrochlorothiazide Zentiva ne smije se koristiti ni kod bolesnika s teškim jetrenim, bubrežnim ili žučnim problemima, s preniskom razinom kalija u krvi ili previsokom razinom kalcija u krvi.
English: For the full list of all side effects reported with Irbesartan Hydrochlorothiazide Zentiva, see the package leaflet.
Croatian: Potpuni popis nuspojava koje su zabilježene s lijekom Irbesartan Hydrochlorothiazide Zentiva potražite u uputi o lijeku.
English: Irbesartan Hydrochlorothiazide Zentiva contains two active substances, irbesartan and hydrochlorothiazide.
Croatian: Irbesartan Hydrochlorothiazide Zentiva sadrži dvije djelatne tvari, irbesartan i hidroklorotiazid.
English: Care must be taken when using Irbesartan Hydrochlorothiazide Zentiva with other medicines that have an effect on blood potassium levels.
Croatian: Hydrochlorothiazide Zentiva s drugim lijekovima koji utječu na razinu kalija u krvi.
English: Irbesartan Hydrochlorothiazide Zentiva is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone.
Croatian: Irbesartan Hydrochlorothiazide Zentiva se koristi kod odraslih bolesnika s esencijalnom hipertenzijom (visokim krvnim tlakom) koja se ne može na odgovarajući način kontrolirati samo irbesartanom ili samo hidroklorotiazidom. „Esencijalna” označava hipertenziju koja nema očitog uzroka.
English: What is the risk associated with Irbesartan Hydrochlorothiazide Zentiva?
Croatian: Koji su rizici povezani s lijekom Irbesartan Hydrochlorothiazide Zentiva?
English: What benefit has Irbesartan Hydrochlorothiazide Zentiva shown during the studies?
Croatian: Koje koristi lijeka Irbesartan Hydrochlorothiazide Zentiva su dokazane tijekom ispitivanja?
English: What is Irbesartan Hydrochlorothiazide Zentiva?
Croatian: Što je Irbesartan Hydrochlorothiazide Zentiva?
English: Why has Irbesartan Hydrochlorothiazide Zentiva been approved?
Croatian: Zašto je lijek Irbesartan Hydrochlorothiazide Zentiva odobren?
English: How is Irbesartan Hydrochlorothiazide Zentiva used?
Croatian: Kako se Irbesartan Hydrochlorothiazide Zentiva koristi?
English: How has Irbesartan Hydrochlorothiazide Zentiva been studied?
Croatian: Kako se Irbesartan Hydrochlorothiazide Zentiva ispitivao?
English: What is Irbesartan Hydrochlorothiazide Zentiva used for?
Croatian: Za što se Irbesartan Hydrochlorothiazide Zentiva koristi?
English: How does Irbesartan Hydrochlorothiazide Zentiva work?
Croatian: Kako Irbesartan Hydrochlorothiazide Zentiva djeluje?
English: • Marketing authorisation under exceptional circumstances The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the marketing authorisation under exceptional circumstances as further explained in the European Public Assessment Report.
Croatian: Nakon razmatranja zahtjeva, mišljenje je CHMP (Povjerenstvo za humane lijekove) da je omjer rizika i koristi povoljan te se može preporučiti izdavanje odobrenja za stavljanje gotovog lijeka u promet u iznimnim okolnostima, a što je dodatno objašnjeno u Europskom javnom izvješću o ocjeni lijeka.
English: Annex IV Conclusions on the granting of the marketing authorisation under exceptional circumstances presented by the European Medicines Agency
Croatian: Zaključci Europske agencije za lijekove o izdavanju odobrenja u iznimnim okolnostima
English: 25 June 2013
Croatian: 25. lipnja 2013.
English: Transmission to National Competent Authorities of the translations of the annexes to the agreement:
Croatian: Predaja nacionalnim nadležnim tijelima za prijevode priloga sporazumu:
English: May 2013 CMDh meeting
Croatian: svibanj 2013., zasjedanje CMDh-a
English: Implementation of the agreement by the Member States:
Croatian: Provedba sporazuma od strane država članica: 25. srpnja 2013.
English: Treatment begins the day after the cataract operation and continues for two weeks.
Croatian: Liječenje započinje dan nakon operacije katarakta i traje dva tjedna.
English: The full EPAR for Yellox can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Yellox nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: In both studies, the main measure of effectiveness was the number of patients with no sign of inflammation after two weeks.
Croatian: U oba je ispitivanja glavno mjerilo djelotvornosti bio broj bolesnika kod kojih su nakon dva tjedna nestali znakovi upale.
English: If more than one eye medicine is being used, they should be given at least five minutes apart.
Croatian: Ako se koristi više vrsta kapi za oči, između njihove primjene mora proći barem pet minuta.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Yellox on 18 May 2011.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Yellox u promet koje vrijedi na prostoru Europske unije od 18. svibnja 2011.
English: This is a summary of the European public assessment report (EPAR) for Yellox.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Yellox.
English: The European Medicines Agency decided that Yellox's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Yellox nadmašuju s njim povezane rizike te je preporučila izdavanje odobrenja za stavljanje tog lijeka u promet.
English: What measures are being taken to ensure the safe and effective use of Yellox?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Yellox?
English: The most common or most important side effects seen with Yellox are abnormal sensation in eye (0.5%), mild or moderate erosion of the cornea (the transparent layer in front of the eye) (0.4%), eye pruritus (itching) (0.4%), eye pain (0.3%) and eye redness (0.3%).
Croatian: Najčešće ili najznačajnije nuspojave zabilježene pri primjeni lijeka Yellox bile su nenormalan osjećaj u oku (0,5 %), blaga ili umjerena erozija rožnice (prozirnog sloja u prednjem dijelu oka) (0,4 %), očni pruritus (svrbež u oku) (0,4 %), bol u oku (0,3 %) i crvenilo oka (0,3 %).
English: Why is Yellox approved?
Croatian: Zašto je Yellox odobren?
English: Other information about Yellox
Croatian: Ostale informacije o lijeku Yellox
English: In one study, 66% of patients treated with Yellox (104 out of 158) had no signs of inflammation after two weeks compared with 48% of patients receiving placebo (35 out of 73).
Croatian: U jednom ispitivanju 66 % bolesnika koji su uzimali lijek Yellox (104 od 158) nije imalo simptome upale nakon dva tjedna, u usporedbi s 48 % bolesnika koji su primili placebo (35 od 73).
English: Yellox bromfenac
Croatian: Yellox bromfenak
English: What is Yellox and what is it used for?
Croatian: Što je Yellox i za što se koristi?